The Chinese Biopharmaceutical Association-USA (CBA) was established in 1995 and is the largest professional
technical association in the United States for Chinese-American biopharmaceutical professionals. The 1st Annual
Chinese Biopharmaceutical Association Conference in China will be held on June 28th-29th in Suzhou Industrial
Park. The conference will also host a start-up enterprise roadshow and networking event to help facilitate the
transformation and acceleration of high-quality biopharmaceutical projects, as well as provide a platform for
interaction between high-quality projects and investment institutions to support the rapid growth of
entrepreneurs and companies.
ChemLex as one of the exhibitors, we will showcase the company's latest research and development achievements
and products, introduce the company's technical strength and service capabilities, and have in-depth exchanges
and cooperation with domestic and foreign scientific and technological enterprises and professionals, jointly
promoting the automation and intelligent synthesis CRO service platform, providing customers with cost-effective
services and ESG value, accelerating innovative drug research and development, and addressing unmet medication
needs of patients.
Dr. Sean Lin, founder and CEO of ChemLex, will attend this conference and participate in the roundtable
discussion. We welcome everyone to pay attention and visit our booth for exchanges.
June 28th
Session Nine: AI and New Technologies
Roundtable Forum 16:20-17:00
How AI and new technologies empower industry upgrades from fundamental research
June 28-29
Exhibition Exchange
Booth number 75
Suzhou International Expo Center
Looking forward to meeting you!
Scan the code to make an appointment for exchange
Thank you for your attention!
About ChemLex
ChemLex, founded in 2022 by an interdisciplinary founding team, is devoted to providing revolutionary CRO
services via AI and high-throughput automation. ChemLex has developed a proprietary automated high throughput
experimentation system that aims to replace medicinal chemists' manual operation, and an AI system that
provides optimal synthetic routes. The big data for AI model training is acquired from ChemLex’s wet lab,
facilitated by the high-throughput automatic synthetic system. AI-driven high-throughput automatic system is
expected to significantly accelerate drug discovery, cut cost and mitigate the pollution to the environment
and safety hazards to operational personnel via "green chemistry".
